Transgenic mouse models

Peritoneal Dialysis International

Volumn 27, Issue 6, 2007, Pages 625-633

  Nishino, Tomoya ^a   Ni, Jie ^b   Devuyst, Olivier ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AGE; Inflammation; Knock out mice; Peritoneum; Peritonitis; RAGE; Transport

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIBIOTIC AGENT; AQUAPORIN 1; CALVASCULIN; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOLL LIKE RECEPTOR 4; AQP1 PROTEIN, MOUSE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NOS3 PROTEIN, MOUSE; RAGE PROTEIN, MOUSE; UNCLASSIFIED DRUG;

C57BL 6 MOUSE; CAPILLARY ENDOTHELIUM; DISEASE MODEL; DNA MODIFICATION; FIBROBLAST; GENETIC MANIPULATION; KIDNEY FAILURE; KNOCKOUT MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; ULTRAFILTRATION; WATER TRANSPORT; ANIMAL; ANIMAL MODEL; CHRONIC KIDNEY FAILURE; GENETICS; MOUSE; PERITONEAL DISEASE; PERITONEUM; PHYSIOLOGY; RABBIT; RAT;

ANIMALS; AQUAPORIN 1; CAVEOLIN 1; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE II; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; RABBITS; RATS; RECEPTORS, INTERLEUKIN-6; ULTRAFILTRATION;

EID: 41049098999     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700604     Document Type: Review

References (56)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20:2587-93.
2. Margetts PJ, Churchill DN. Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002; 13:2787-94.
3. Gillerot G, Devuyst O. Molecular mechanisms involved in the peritoneal membrane exposed to peritoneal dialysis. Clin Nephrol 2003; 60:1-6.
4. Krediet RT. The physiology of peritoneal solute transport and ultrafiltration. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000: 135-72.
5. Lameire N, Van Biesen W, Mortier S, De Vriese A. What did we learn from animal models in peritoneal dialysis? Contrib Nephrol 2006; 150:70-6.
6. Carlsson O, Nielsen S, Zakaria el-R, Rippe B. In vivo inhibition of transcellular water channels (aquaporin-1) during acute peritoneal dialysis in rats. Am J Physiol 1996; 271:H2254-H2262.
7. Ferrier ML, Combet S, van Landschoot M, Stoenoiu MS, Cnops Y, Lameire N, et al. Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 2001; 60:2343-50.
8. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12:1734-41.
9. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
10. Russell JC. Of mice and men, rats and atherosclerosis. Cardiovasc Res 2003; 59:810-11.
11. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, et al. Of mice and models: improved animal models for biomedical research. Physiol Genomics 2002; 11:115-32.
12. Van der Weyden L, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol Genomics 2002; 11:133-64.
13. Rao S, Verkman AS. Analysis of organ physiology in transgenic mice. Am J Physiol Cell Physiol 2000; 279: C1-C18.
14. Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14: 3205-16.
15. Ni J, Cnops Y, Debaix H, Boisdé I, Verbavatz JM, Devuyst O. Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int 2005; 67:2021-31.
16. Gotloib L, Shostak A, Wajsbrot V. Functional structure of the peritoneum as a dialysing membrane. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000: 37-106.
17. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, et al.; EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14: 2948-57.
18. Rippe B, Stelin G, Haraldsson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991; 40: 315-25.
19. Rippe B, Venturoli D, Simonsen O, de Arteaga J. Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int 2004; 24:10-27.
20. Agre P. Aquaporin water channels [Nobel Lecture]. Angew Chem Int Ed Engl 2004; 43:4278-90.
21. Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci U S A 1993; 90:7275-9.
22. Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Goffin E. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 1998; 275:H234-H242.
23. Combet S,van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, et al. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 1999; 10:2185-96.
24. Yang B, Folkesson HG, Yang J, Matthay MA, Ma T, Verkman AS. Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. Am J Physiol 1999; 276:C76-C81.
25. Ni J, Verbavatz JM, Rippe A, Boisdé I, Moulin P, Rippe B, et al. Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 2006; 69:1518-25.
26. Stoenoiu MS, Ni J, Verkaeren C, Debaix H, Jonas J-C, Lameire N, et al. Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum. J Am Soc Nephrol 2003; 14:555-65.
27. Predescu D, Palade GE. Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. Am J Physiol 1993; 265:H725-H733.
28. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8:185-94.
29. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000; 6:1362-7.
30. Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001; 276:48619-22.
31. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. J Biol Chem 2002; 277: 40091-8.
32. Rosengren BI, Rippe A, Rippe C, Venturoli D, Swärd K, Rippe B. Transvascular protein transport in mice lacking endothelial caveolae. Am J Physiol Heart Circ Physiol 2006; 291:H1371-H1377.
33. Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987; 17:43-52.
34. Douma CE, de Waart DR, Zamel D, Imholz AL, Koomen GC, Struijk DG, et al. Nitrate in stable CAPD patients and during peritonitis. Adv Perit Dial 1995; 11:36-40.
35. Combet S, Balligand JL, Lameire N, Goffin E, Devuyst O. A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney Int 2000; 57:332-8.
36. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997; 30:311-33.
37. Ni J, Cnops Y, McLoughlin RM, Topley N, Devuyst O. Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int 2005; 25(Suppl 3):S11-14.
38. Bellingan GJ, Caldwell H, Howie SEM, Darnsfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation. J Immunol 1996; 157: 2577-85.
39. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an anti-inflammatory cytokine required for controlling local and systemic acute inflammatory responses. J Clin Invest 1998; 101:311-20.
40. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43-58.
41. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14.
42. McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, et al. Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 2003; 112: 598-607.
43. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005; 102:9589-94.
44. Miyata T, Devuyst O, Kurokawa K. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61:375-86.
45. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498:99-111.
46. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-56.
47. Boulanger E, Grossin N, Wautier MP, Taamma R, Wautier JL. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007; 71:126-33.
48. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207.
49. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, et al. Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 2003; 64:1722-32.
50. Dobbie J. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
51. Okada H, Danoff T, Fischer A, Lopez-Guiss JM, Strutz F, Neilson EG. Identification of a novel cis-acting element for fibroblast-specific transcription of the FSP1 gene. Am J Physiol 1998; 275:F306-F314.
52. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, Neilson EG. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 2000; 58:587-97.
53. Iwano M, Fischer A, Okada H, Plieth D, Xue C, Danoff TM, et al. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther 2001; 3:149-59.
54. Kato S, Yuzawa Y, Tsuboi N, Maruyama S, Morita Y, Matsuguchi T, et al. Endotoxin-induced chemokine expression in murine peritoneal mesothelial. cells: the role of toll-like receptor 4. J Am Soc Nephrol 2004; 15:1289-99.
55. Robson LR, McLouglin MR, Witowski J, Loetscher P, Wilkinson TS, Jones SA, et al. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-γ controls neutrophil migration across the mesothelium in vitro and in vivo. J Immunol 2001; 167: 1028-38.
56. Tsuboi N, Yoshikai Y, Matsuo S, Kikushi T, Iwami K, Nagai Y, et al. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol 2002; 169:2026-33.